226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 143 / Drugs : 171 - (DrugBank : 56) / Drug target genes : 64 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04313972 (ClinicalTrials.gov) | September 7, 2021 | 16/3/2020 | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial | Interstitial Cystitis;Painful Bladder Syndrome;Bladder Pain Syndrome;Low Dose Naltrexone;Low-dose Naltrexone;Naltrexone | Drug: low-dose naltrexone;Drug: Placebo oral tablet | NorthShore University HealthSystem | NULL | Recruiting | 18 Years | 110 Years | Female | 44 | Phase 4 | United States |
| 2 | NCT04450316 (ClinicalTrials.gov) | October 8, 2020 | 24/6/2020 | Low-dose Naltrexone for Bladder Pain Syndrome | Low-dose Naltrexone for Bladder Pain Syndrome: A Randomized Placebo-controlled Prospective Pilot Trial | Bladder Pain Syndrome;Interstitial Cystitis | Drug: Naltrexone;Drug: Placebo | Stanford University | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | United States |